Senores Pharmaceuticals Q1 FY27 Earnings Call Transcript Highlights: Management Targets 30–40% Revenue Growth in FY27

Senores Pharmaceuticals Limited has released the transcript of its Q1 FY27 Earnings Conference Call, offering investors deeper insights into the company’s growth strategy, financial performance, product pipeline, manufacturing expansion, and outlook for FY27 and beyond.

Management expressed confidence in maintaining strong growth momentum, supported by a rapidly expanding ANDA portfolio, strategic acquisitions, manufacturing capacity expansion, and increasing global market presence.

Strong Q1 FY27 Financial Performance

The company reported another strong quarter, with robust growth across both regulated and emerging markets.

Q1 FY27 Financial Highlights

• Revenue from Operations: ₹180 crore, up 36% YoY
• Regulated Markets Revenue: Up 42% YoY
• Emerging Markets Revenue: Up 30% YoY
• India Branded Generics Revenue: ₹8 crore
• EBITDA: ₹54 crore, up 87% YoY
• EBITDA Margin: Nearly 30%, improving by 810 basis points
• Profit After Tax (PAT): ₹31 crore, up 56% YoY

Management attributed the strong performance to disciplined execution, operational excellence, diversified geographic presence, and an expanding portfolio of differentiated pharmaceutical products.

FY27 Guidance Remains Strong

During the conference call, management reaffirmed its optimistic outlook for FY27.

The company expects:

• Revenue Growth: Approximately 30%–40%
• PAT Growth: Around 50%–60%

Management also indicated that a similar growth trajectory could continue in subsequent years, backed by product launches and global expansion.

Expanding ANDA Portfolio Strengthens US Business

One of the biggest growth drivers remains Senores’ regulated markets business.

Key developments include:

• Approved ANDAs increased from 30 in June 2025 to 58 by June 2026
• 23 ANDAs have already been commercialized
• Remaining 35 approved ANDAs are expected to be commercialized over the next 18–20 months
• Pipeline includes 39 additional molecules covering more than 110 strengths

Management said commercialization strategies, marketing partnerships, and manufacturing readiness have already been established, providing strong execution visibility.

Strategic Manufacturing Expansion

The acquisition of the Apnar USFDA-approved manufacturing facility in Vadodara continues to strengthen Senores’ manufacturing capabilities.

According to management:

• Production has already ramped up significantly.
• Around 30 million units were produced during Q1 FY27.
• Six products have already been commercialized from the facility.
• Capacity expansion through additional production lines is underway.

Management also noted that the facility is operating at approximately 80–90% production utilization, with additional investments planned to support future launches.

US Commercial Platform Continues to Expand

The company is strengthening its presence in the United States through multiple commercial channels.

These include:

• Zoraya Pharma for front-end branded sales
• Amerisyn focused on government business
• B2B licensing partnerships
• CDMO and CMO operations

Management expects both Zoraya and Amerisyn to begin operations during the second half of FY27.

Emerging Markets Deliver Healthy Growth

Emerging markets remained another important contributor.

Highlights include:

• Revenue growth of approximately 30%
• EBITDA margins improving to the mid-teen range
• Business becoming cash-flow positive

Management revealed that the emerging markets business generated approximately ₹18 crore in operating cash flow during the quarter.

The company is also pursuing European PIC/S certification for its Chhatral manufacturing facility, which could open opportunities in countries such as:

• South Africa
• Vietnam
• Mexico
• Other regulated mid-tier international markets

Long-Term Growth Pipeline Looks Robust

Senores believes its current pipeline provides strong visibility over the next several years.

Management highlighted:

• 58 approved ANDAs
• 39 additional molecules under development
• More than 900 product registrations pending in emerging markets
• Approximately 500 products already approved across emerging markets

The company expects these approvals and launches to drive sustained revenue growth over the medium term.

Revenue Vision of ₹2,500–3,000 Crore

Management reiterated its long-term ambition of reaching:

• ₹2,500 crore to ₹3,000 crore annual revenue within the next three to four years

Importantly, this target excludes potential contributions from future NDA products currently under development, leaving room for additional upside.

Capital Allocation Strategy Updated

Management also discussed changes in the utilization of IPO proceeds.

Instead of investing aggressively in a large sterile injectables facility immediately, the company plans to:

• Expand oral solid manufacturing capacity
• Develop a smaller pilot injectable facility
• Focus capital on businesses generating faster returns

The sterile injectables strategy remains part of the company’s long-term roadmap.

Management on US Tariff Concerns

Responding to investor questions about possible US tariffs on imported generic medicines, management adopted a cautious approach.

The company stated it would wait for the final India-US trade agreement before assessing any impact.

Since Senores already has manufacturing capabilities in both India and the United States, management believes it is relatively well-positioned to navigate any policy changes.